छोड़कर सामग्री पर जाएँ

Sun Pharma profit may decline 10% in Q3 on poor operating performance

Company likely to report a muted operating performance in Q3FY23, with an EBITDA margin growth estimated flat at 26.2 percent on a year-on-year (YoY) basis. Analysts attribute the steady sale of its specialty products in the US to aid EBITDA margin growth.

Read More

​ Company likely to report a muted operating performance in Q3FY23, with an EBITDA margin growth estimated flat at 26.2 percent on a year-on-year (YoY) basis. Analysts attribute the steady sale of its specialty products in the US to aid EBITDA margin growth. Company likely to report a muted operating performance in Q3FY23, with an EBITDA margin growth estimated flat at 26.2 percent on a year-on-year (YoY) basis. Analysts attribute the steady sale of its specialty products in the US to aid EBITDA margin growth.  Moneycontrol Latest News Read More  

प्रातिक्रिया दे

आपका ईमेल पता प्रकाशित नहीं किया जाएगा. आवश्यक फ़ील्ड चिह्नित हैं *

hi_INहिन्दी